Clinical Trials Directory

Trials / Completed

CompletedNCT00179413

Study of Long-term Peg Intron vs. Colchicine in Non-responders.

Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
549 (actual)
Sponsor
Beth Israel Deaconess Medical Center · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

In this study Peg-Intron will be tested to see if it will give better results than Colchicine. At this time, there is currently no recommended maintenance treatment for patients who have failed to respond to Interferon/Rebetron/Peg Intron and have advanced fibrosis. The purpose of this study is to compare two treatments to slow down the progression of liver disease and to prevent liver failure and liver cancer. The treatment will not cure Hepatitis C, but is being evaluated to see if it can slow down disease progression.

Detailed description

We are proposing a randomized trial of Peg-Intron 0.5mcg per kg weekly versus colchicine 0.6mg bid in prior non-responders to Interferon, Rebetron, PegIntron, or PegIntron \& Ribavirin or any third agent such as Pegasys, CellCept, Amantadine with advanced fibrosis/cirrhosis. The specific aims of this proposal are to evaluate the role of long term Peg-Intron therapy on the natural history of patients with advanced chronic HCV infection with a primary focus on prevention of hepatic decompensation, progression of fibrosis and hepatoma development. The study design will focus on 3 monthly clinical evaluation for decompensation of liver function, rigorous clinical screening for development of hepatocellular cancer and liver biopsies for determination of progression of liver fibrosis every second year.

Conditions

Interventions

TypeNameDescription
DRUGPEG -Intron
DRUGColchicine0.6mg twice a day

Timeline

Start date
2000-01-15
Primary completion
2009-12-31
Completion
2010-03-03
First posted
2005-09-16
Last updated
2017-07-11
Results posted
2017-07-11

Locations

49 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00179413. Inclusion in this directory is not an endorsement.